Business
HealthMed Services Ltd., Announces Memorandum Of Understanding With Advanced Prenatal Therapeutics, Inc.
HealthMed Services Ltd., Announces Memorandum Of Understanding With Advanced Prenatal Therapeutics, Inc..
About this update from Polomar Health Services, Inc.
[{"type":"text","content":"\n\n\n\nHealthMed Services Ltd., Announces Memorandum Of Understanding With Advanced Prenatal Therapeutics, Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nHealthMed Services Ltd., Announces Memorandum Of Understanding With Advanced Prenatal Therapeutics, Inc.\nPR Newswire\nPALM DESERT, Calif., Feb. 28, 2019\n\n\n\nPALM DESERT, Calif., Feb. 28, 2019 /PRNewswire/ -- HealthMed Services, Ltd., (OTC Pink – HEME – News) announced today that it has entered into a Memorandum of Understanding to form a Joint Venture between Advanced Prenatal Therapeutics, Inc. (APT) and a new distribution company, to be formed by HealthMed to distribute products that have been invented and.or patented by APT.\nDr. James Smith. Ph. D said, \"APT has several patents either granted or pending that cover a broad range of Apheresis technology for the treatment of preeclampsia.  Preeclampsia is a leading cause of prematurity and intrauterine growth restriction which leads to lifelong challenges for a baby.  It is also the leading cause of maternal illness, and approximately 20% of maternal deaths.\"   Dr. Smith went on to say, \"Approximately 10,000 babies die each year in the U.S., and approximately 500,000 worldwide from preeclampsia and we are looking forward in establishing a new distribution company that will JV with HealthMed Services Advanced Prenatal to distribute various products of APT.\"  (See www.advancedprenatal.com)\nJames Shipley, President of HealthMed Services, Ltd., said, \"APT will offer a broad portfolio and oral drug delivery technology platforms, including Bioavailability, as well as enhanced and customized drug release.  APT's flexible technology platforms  will enable the new Joint Venture and its distribution partners to provide  customized drug formulation solutions across a range of dosage forms and therapies.\"  Mr. Shipley went on to say, \"We are looking forward to building a broad global distribution company and working with Dr. James Smith.\"   \nAbout HealthMed Services Ltd.\nHealthMed Service...